Targeted therapies in hematology and their impact on patient care: Chronic and acute myeloid leukemia

Seminars in Hematology

Volumn 50, Issue 4, 2013, Pages 271-283

  Jabbour, Elias ^a   Cortes, Jorge ^a   Ravandi, Farhad ^a   O'Brien, Susan ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BISMUTH 213; BOSUTINIB; CD135 ANTIGEN; CLADRIBINE; CLOFARABINE; CRENOLANIB; CYTARABINE; DASATINIB; DAUNORUBICIN; FLUDARABINE; GEMTUZUMAB; GEMTUZUMAB OZOGAMICIN; HOMOHARRINGTONINE; IMATINIB; INTERFERON; LESTAURTINIB; LINTUZUMAB; MIDOSTAURIN; MONOCLONAL ANTIBODY; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; REBASTINIB; SL 401; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOSAROXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HUMAN; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; PATIENT CARE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; THROMBOCYTOPENIA; TORSADE DES POINTES;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; PATIENT CARE; PROTEIN KINASE INHIBITORS;

EID: 84887511479     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.09.006     Document Type: Article

References (91)

1. Huang X., Cortes J., Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012, 118:3123-3127.
2. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243(5405):290-293.
3. Mandanas R.A., Leibowitz D.S., Gharehbaghi K., et al. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993, 82(6):1838-1847.
4. Okuda K., Matulonis U., Salgia R. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 1994, 22(11):1111-1117.
5. Raitano A.B., Halpern J.R., Hambuch T.M. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 1995, 92(25):11746-11750.
6. Sawyers C.L., Callahan W., Witte O.N. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992, 70(6):901-910.
7. Shuai K., Halpern J., ten Hoeve J. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996, 13(2):247-254.
8. Carlesso N., Frank D.A., Griffin J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996, 183(3):811-820.
9. Ilaria R.L., Van Etten R.A. P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996, 271(49):31704-31710.
10. Silver R.T., Woolf S.H., Hehlmann R., et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999, 94(5):1517-1536.
11. Deininger M., O'Brien S.G., Guilhot F., et al. International randomized study of interferon v STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression of events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, 114. (abstract).
12. National Cancer Institute. SEER stat fact sheets: acute myeloid leukemia. 2012. Bethesda, MD. Accessed April 2013.
13. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100(13):4325-4336.
14. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366(12):1079-1089.
15. Druker B.J., Lydon N.B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000, 105(1):3-7.
16. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11):994-1004.
17. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
18. O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65(11):4500-4505.
19. Tokarski J.S., Newitt J.A., Chang C.Y., et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006, 66(11):5790-5797.
20. Shah N.P., Tran C., Lee F.Y., et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305(5682):399-401.
21. Kantarjian H., Shah N.P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(24):2260-2270.
22. Shah N.P., Cortes J.E., Baccarani M., et al. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. J Clin Oncol 2012, 30(suppl). abstr 6504.
23. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7(2):129-141.
24. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(24):2251-2259.
25. Kantarjian H.M., Kim D.-W., Issaragrisil S., et al. Enestnd 4-year (y) update: continued superiority of nilotinib vs imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP). ASH Annual Meeting Abstracts 2012, 120:1676.
26. Marin D., Bazeos A., Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28(14):2381-2388.
27. Darkow T., Henk H.J., Thomas S.K., et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007, 25(6):481-496.
28. Noens L., van Lierde M.A., De Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113(22):5401-5411.
29. Jabbour E., Kantarjian H.M., Jones D., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113(10):2154-2160.
30. Garcia-Gutierrez J.V., Herrera P., Abalo L.L., Rey M.D., Calbacho M. Impact of second-generation tyrosine kinase inhibitors as second line treatment for patients with chronic myeloid leukemia. Blood 2011, 118:632.
31. Goh H.G., Jootar S., Kim H.J., Sohn S.K., Park J.S., Kim S.H. Efficacy of nilotinib versus high-dose imatinib in early chronic phase CML patients who have suboptimal molecular responses to standard-dose imatinib (RE-NICE multicenter study). Blood 2011, 118:632.
32. Kantarjian H., Pasquini R., Levy V., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136-4147.
33. Yeung D.T., Osborn M., White D.L., Branford S., Kornhauser M., Slader C. Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression- an update of the TIDEL-II trial. Blood 2011, 118:632.
34. Quintas-Cardama A., Cortes J.E., O'Brien S., et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009, 115:2912-2921.
35. O'Hare T., Shakespeare W.C., Zhu X., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16(5):401-412.
36. Cortes J.E., Kantarjian H., Shah N.P., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012, 367:2075-2088.
37. Cortes J.E., Kim D.-W., Pinilla-Ibarz J., et al. A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial. ASH Annual Meeting Abstracts 2012, 120:163.
38. Chan W.W., Wise S.C., Kaufman M.D., Ahn Y.M., Ensinger C.L., Haack T., et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011, 19(4):556-568.
39. Quintas-Cardama A., Kantarjian H., Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009, 115(23):5382-5393.
40. Gontarewicz A., Balabanov S., Keller G., et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008, 111(8):4355-4364.
41. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
42. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
43. O'Brien SAC, Akhtari M, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Available at. Version 2, 2013. http://NCCN.org.
44. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
45. Baccarani M., Rosti G., Castagnetti F., et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497-4504.
46. NCCN: National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. (NCCN Guidelines®). NCCN Version 4. 2013.
47. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
48. Hughes T., Hochhaus A., Branford S., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116:3758-3765.
49. Kantarjian H., O'Brien S., Shan J., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Need for new response definitions?. Cancer 2008, 112:837-845.
50. Hehlmann R., Lauseker M., Jung-Munkwitz S., et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011, 29:1634-1642.
51. de Lavallade H., Apperley J.F., Khirashad J.S., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-3363.
52. Jabbour E., Kantarjian H., O'Brien S., et al. The achievement of an early complete cytogenetic response is a major determinant of outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011, 118:4541-4546.
53. Hanfstein B., Muller M.C., Hehlmann R., et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012, 26:2096-2102.
54. Saglio G., Kantarjian H.M., Shah N., et al. Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data. Blood 2012, 120. (abstract).
55. Hochhaus A., Hughes T.P., Saglio G., et al. Outcome of patients with chronic myeloid leukemia in chronic phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials newly diagnosed patients). Blood 2012, 120(suppl). abstract 167.
56. Marin D., Ibrahim A.R., Lucas C., et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012, 30:232-238.
57. Neelakantan P., Gerrard G., Foroni L., et al. Can the combination of the measurement of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement?. Blood 2012, 120(suppl). abstract 68.
58. Jain P., Kantarjian H., Nazha A., et al. Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 2013, 121(24):4867-4874.
59. Kantarjian H.M., Shan J., Jones D., et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009, 27:3659-3663.
60. Mahon F.X., Réa D., Guilhot J., et al. Intergroupe Français des leucémies myéloïdes chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 2010, 11:1029-1135.
61. Mahon F.X., Réa D., Guilhot J., et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study. Blood 2011, 118. (abstract 603).
62. Fathi A., Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol 2011, 18(2):71-76.
63. Mead A.J., Gale R.E., Hills R.K., et al. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 2008, 112:444-445.
64. DeZern A.E., Sung A., Kim S., et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 2001, 17(9):1404-1409.
65. Smith C.C., Wang Q., Chin C.S., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485(7397):260-263.
66. Levis M., Ravandi F., Wang E.S., et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011, 117(12):3294-3301.
67. Sato T., Yang X., Knapper S., et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011, 117(12):3286-3293.
68. Fischer T., Stone R.M., DeAngelo D.J., et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010, 28(28):4339-4345.
69. Nexavar (sorafenib) package insert. Wayne, NJ. Bayer Healthcare Pharmaceuticals, Inc. 12/2012.
70. Borthakur G., Kantarjian H., Ravandi F., et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2011, 96(1):62-68.
71. Metzelder S., Wang Y., Wollmer E., et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113(26):6567-6571.
72. Ravandi F., Alattar M.L., Grunwald M.R., et al. Phase II study of azacitidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013, 121(23):4655-4662.
73. Zarrinkar P.P., Gunawardane R.N., Cramer M.D., et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia. Blood 2009, 114(14):2984-2992.
74. Cortes J.E., Perl A.E., Dombret H., et al. Final results of a phase 2 open-label monotherapy efficacy and safety study of quizartinib (AC220) in patients > 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2012, 120. abstract 48.
75. Levis M.J., Perl A.E., Dombret H., et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2012, 120. abstract 673.
76. Jabbour E., Branford S., Saglio G., et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011, 117(9):1800-1811.
77. Smith C.C., Lasater E., McCreery M., et al. Crenolanib (CP-868,596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistance-causing FLT3 kinase domain mutations. Blood (ASH Annual Meeting Abstracts) 2012, 120. abstract 141.
78. Petersdorf S.H., Kopecky K.J., Slovak M., et al. A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia. Blood 2013, 121(24):4854-4860.
79. Ravandi F., Estey E.H., Appelbaum F.R., et al. Gemtuzumab ozogamicin: time to resurrect?. J Clin Oncol 2012, 30(32):3921-3923.
80. Castaigne S., Pautas C., Terre C., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379(9825):1508-1516.
81. Burnett A.K., Hills R.K., Milligan D., et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC 15 trial. J Clin Oncol 2011, 29(4):369-377.
82. Burnett A.K., Russell N.H., Hills R.K., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012, 30(32):3924-3931.
83. Estey E.H., Giles F.J., Beran M., et al. Experience with gemtuzumab ozogamycin ("Mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002, 99:4222-4224.
84. Ravandi F., Estey E., Jones D., et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009, 27:504-510.
85. Lo-Coco F., Cimino G., Breccia M., et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004, 104:1995-1999.
86. Estey E. Treatment of AML: resurrection for gemtuzumab ozogamicin?. Lancet 2012, 379(9825):1468-1469.
87. Jurcic J.G. What happened to anti-CD33 therapy for acute myeloid leukemia?. Curr Hematol Malig Rep 2012, 7(1):65-73.
88. Feldman E.J., Brandwein J., Stone R., et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005, 23(18):4110-4116.
89. lancet J.E., Sekeres M.A., Wood B.L., et al. Lintuzumab and low-dose cytarabine compared to placebo and low-dose cytarabine in patients with untreated acute myeloid leukemia 60 years and older: results of a randomized, double-blind phase 2b study. Blood 2011, 118. abstract 3613.
90. Rosenblat T.L., McDevitt M.R., Mulford D.A., et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010, 16(21):5303-5311.
91. Konopleva M., Hogge D.E., Rizzieri D.A., et al. SL-401, a targeted therapy directed to the interleukin-3 receptor present on leukemia blasts and cancer stem cells, is active as a single agent in patients with advanced AML. Blood 2012, 120. abstract 3625.